Chlorambucil in chronic lymphocytic leukemia: mechanism of action.

@article{Begleiter1996ChlorambucilIC,
  title={Chlorambucil in chronic lymphocytic leukemia: mechanism of action.},
  author={Asher Begleiter and Michael R A Mowat and LyonelG. Israels and James B. Johnston},
  journal={Leukemia & lymphoma},
  year={1996},
  volume={23 3-4},
  pages={
          187-201
        }
}
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries but the clinical presentation and rate of disease progression are highly variable. When treatment is required the most commonly used therapy is the nitrogen mustard alkylating agent, chlorambucil (CLB), with or without prednisone. Although CLB has been used in the treatment of CLL for forty years the exact mechanism of action of this agent in CLL is still unclear. Studies in proliferating model tumor systems… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Reactive oxygen species‐responsive nanoprodrug with quinone methides‐mediated GSH depletion for improved chlorambucil breast cancers therapy

VIEW 3 EXCERPTS
CITES BACKGROUND